---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic burden and healthcare resource utilization"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic burden and healthcare resource utilization. Topics: All-cause healthcare costs and resource use in U.S. commercial, Medicare, and Medicaid claims; Healthcare costs by treatment type and adverse event-related costs in U.S. commercial and Medicare claims; Hospital resource use and inpatient costs in NHS England; Inpatient administration of tebentafusp during dose escalation in practice. 4 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/economic-burden-and-healthcare-resource-utilization"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic burden and healthcare resource utilization

<a id="heading-2.2.1.8.2"></a>

## 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

### All-cause healthcare costs and resource use in U.S. commercial, Medicare, and Medicaid claims

> “This study was conducted using the Merative MarketScan Commercial, Medicare, and Multi-State Medicaid Databases.”
> “In total 471 mUM patients were included; 47% Commercially-insured, 43% Medicare, and 10% Medicaid patients.”
> “Mean healthcare costs were $29,187 per patient per month (PPPM) (SD: $46,089) and included inpatient and outpatient medical costs, and outpatient pharmacy costs.”
> “Inpatient costs were $6,502 PPPM (SD: $28,591) overall, including $4,049 PPPM (SD: $23,619) for ICU admissions.”
> “Outpatient medical services (i.e., ER, office, labs, radiology, treatments) were $20,555 PPPM (SD $24,272).”
> “Outpatient pharmacy costs were $2,131 PPPM (SD $5,448).”
> “Most expenditures in mUM patients are associated with outpatient medical services; ICU admissions accounted for ≥60% of inpatient expenditures.”

Source: [Ott et al. (2026a)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-europe-2026/poster-session-3-4/clinical-and-economic-burden-of-metastatic-uveal-melanoma-a-retrospective-analysis-of-commercially-insured-medicare-and-medicaid-patients-in-the-united-states)

<a id="topic-2.2.1.8.2-2"></a>

### Healthcare costs by treatment type and adverse event-related costs in U.S. commercial and Medicare claims

> “Costs were calculated from paid amounts on adjudicated claims, including insurer/health plan payments and patient out of pocket payments; actual costs (vs. imputed costs) were available for most patients.”
> “Healthcare costs were measured during the variable follow-up period in Commercial and Medicare patients.”
> “Mean PPPM all-cause costs were highest in patients treated with tebentafusp (Figure 3).”
> “Adverse event-related costs were highest among patients treated with tebentafusp but were the highest percentage of total costs in patients treated with chemotherapy (Figure 4).”
> “In this claims-based analysis, only half of mUM patients received any systemic treatment and 19% received liver directed therapy.”

Source: [Ott et al. (2026b)](https://www.ispor.org/docs/default-source/cti-meeting-21555-documents/38342afa-bde4-4633-bef6-da8a6d3fd1ee.pdf?sfvrsn=608231d6_0)

| Treatment group (Commercial and Medicare patients) | Mean all-cause healthcare costs per patient per month (2025 US$) | Mean adverse event-related costs per patient per month (2025 US$) | Adverse event-related costs as a percentage of all-cause costs |
| --- | --- | --- | --- |
| All patients (n=423) | “$28,859” | “$2,607” | “9.0%” |
| Chemotherapy (n=77) | “$30,682” | “$3,944” | “12.9%” |
| Checkpoint inhibitors (n=145) | “$36,056” | “$4,158” | “11.5%” |
| Tebentafusp (n=39) | “$93,805” | “$6,746” | “7.2%” |
| Liver directed therapy (n=80) | “$35,509” | “$3,078” | “8.7%” |

Source: [Ott et al. (2026b)](https://www.ispor.org/docs/default-source/cti-meeting-21555-documents/38342afa-bde4-4633-bef6-da8a6d3fd1ee.pdf?sfvrsn=608231d6_0)

<a id="topic-2.2.1.8.2-3"></a>

### Hospital resource use and inpatient costs in NHS England

> “A cohort of UM (ICD-10 codes C693 or C694) patients that developed a subsequent cancer code (indicating metastasis), were identified within HES (observational period: Apr2012-Jun2016, follow-up until Jan2017).”
> “This analysis excluded costs not captured within HES (e.g. High Cost Drugs, Specialised Services, non-hospital palliative care).”
> “28% of patients were treated ≥40 km from home; and chemo-/immunotherapy was the most frequent medical procedure delivered (112 patients, 25%).”
> “Over the observed period, the cost to NHSE for mUM inpatient admissions was £2.5 million (mean: £6,084 per patient; range: £224-58,854). The cohort attended 3,618 outpatient appointments and had 669 A&E visits.”

Source: [Cheng et al. (2017)](https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-20th-annual-european-congress/quantifying-standard-of-care-soc-hospital-related-resource-utilisation-for-metastatic-uveal-melanoma-mum-patients-in-nhs-england-nhse-using-the-hospital-episodes-statistics-hes-dataset)

<a id="topic-2.2.1.8.2-4"></a>

### Inpatient administration of tebentafusp during dose escalation in practice

> “We assessed MUM pts treated with TEBE at our center from Jun/2021-Nov/2022.”
> “We identified 36 pts.”
> “The median number of inpatient doses was 4 (3-18). In the OP setting, 19 pts (53%) were switched to q3 week visits after a median of 6 doses (6-39).”
> “Our data supports the reduction of OP visits and holding premedication after the resolution of AE.”

Source: [Ribeiro et al. (2023)](https://www.annalsofoncology.org/article/S0923-7534%2823%2903102-2/fulltext)

> “Inpatient admission is recommended for the dose escalation for CRS monitoring and to provide appropriate supportive treatment.”
> “Fifteen patients received therapy, 47% (n=7) experienced CRS Grade 2 or above (Grade 2 n=5, 33%; Grade 3 n=2, 13%) versus 77% of patients in the trial setting.”
> “Future research should explore a larger real-world patient cohort to identify high-risk patients, removing the requirement for inpatient admission during dose escalation for low-risk patients.”

Source: [Roth et al. (2024)](https://cosa-2024.p.asnevents.com.au/days/2024-11-14/abstract/108393)

> “However, tebentafusp posed new challenges, requiring hospitalisation at commencement and long-distance travel for weekly infusions over an indeterminant period with no breaks”

Source: [Luckett et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12105258/)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
